PALM BEACH, Florida, June 21, 2018 /PRNewswire/ --
MarketNewsUpdates.com News Commentary
Thereis a strong focus on developing technologies to dramatically impact and indentify the causes of the rising number of vision problems affecting more and more individuals. This requires taking an interdisciplinary approach to technology development that
Eyecarrot Innovations Corp (TSX-V:EYC.V) (OTCQB:EYCCF) BREAKING NEWS: Eyecarrot Innovations is pleased to announce that it has initiated delivery of the Binovi Touch Saccadic Fixator to some of the top Academic Institutions in North America. The company is now working with leading vision researchers from universities in the United States such a University of California Berkeley, The State University of New York (SUNY), and Florida State University to accelerate use of the Binovi Platform in developing further research in human vision performance gains.
"Our company has moved from conceptual design, to now fulfilling shipments to World Class Institutions in the United States in under 24 months. We can now accelerate further expansion into the market and extend the reach of our Binovi Touch globally." Stated CEO Adam Cegielski.
The company has now shipped 100 units of the Binovi Touch vision performance hardware since release 2 months ago. This represents a year over year growth in unit sales of over 500% since 2017. The company continues to receive significant interest and increase in sales while showcasing its hardware at the 48th Annual College of Optometrists in Vision Development Meeting.
"Recent feedback from the market has emphasized the utility of the Binovi Touch, as our customers are using the product every day and on every patient. We are pleased with this increase in demand, and overall reception of our platform. Optometrists are appreciating the expanded feature sets, their therapy teams are embracing the modernization, and their patients are thrilled with overall performance. Our next steps are working towards increasing production and carrying inventory of our flagship product with the intent of replacing the 5,000 analog models currently in the market." Commented CEO Adam Cegielski. Read this and more news for Eyecarrot Innovations at: http://www.marketnewsupdates.com/news/eyc.html Additional industry related developments from around the markets:
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye announced this week that it received a close-out letter from the U.S. Food and Drug Administration (FDA) on June 19, 2018 lifting a Warning Letter dated May 21, 2014. "The lifting of the Warning Letter is the result of a comprehensive remediation program that not only addressed the issues raised by the FDA in the 2014 Warning Letter, but included the assessment, remediation and upgrade of all aspects of STAAR's quality systems to assure compliance with Quality System Regulations (QSR)," said Caren Mason, President and CEO. "We have steadfastly initiated and promoted a Culture of Quality which emphasizes prevention and accountability throughout the organization. We are committed to continuing and strengthening this companywide emphasis on excellence."
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, recently announced the filing of an Investigational Device Exemption (IDE) supplement for Punctate Epitheliopathy (PE), using the Company's Ocular Bandage Gel (OBG) product. EyeGate OBG is a cross-linked thiolated carboxymethyl hyaluronic acid (CMHA-S) platform being developed for the acceleration of re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK) and punctate epitheliopathies. PE represents an unmet medical need and is an opportunity for EyeGate's OBG platform to expand to additional indications. There are over 76 million patients with corneal epitheliopathies in the United States. Current treatment approaches are limited, and may include artificial tears, increasing humidity, usage of lubricants/ointments and, in severe cases, the utilization of bandage contact lenses, antibiotics and/or anti-inflammatory/immunomodulatory agents.
Novartis AG (NYSE:NVS) closed up slightly on Wednesday at $74.23 trading over 1.4 million shares by the market close. Novartis researches, develops, manufactures, and markets a range of healthcare products worldwide. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers.
National Vision Holdings, Inc. (NASDAQ:EYE) one of the nation's largest optical retailers providing quality, affordable eye care and eyewear, announced this month the selection of five high school seniors as recipients of the 2018 National Vision College Scholarship Program. Recipients will receive $2,500 to fund the advancement of their education. The award is renewable for up to three additional years, for a total potential scholarship of $10,000 per student. "We are honored to play a role in furthering the academic achievements of members of our National Vision family," said Reade Fahs, Chief Executive Officer of National Vision. "We would like to congratulate all five scholarship winners and wish each one of them success throughout their college journey and future career."
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated forty five hundred dollars for news coverage of the current press release issued above by Eyecarrot Innovations Corp by a non affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Media Contact: email: firstname.lastname@example.org +1(561)325-8757
Subscribe to our Free Newsletters!